Project Grant R01HL176912
- This federal Project Grant award of $159,624.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at Vanderbilt University Medical Center (VUMC) to investigate the role of hypoxia-inducible factor (HIF) in promoting alveolar regeneration and functional lung repair for patients with idiopathic pulmonary fibrosis (IPF) and other chronic lung diseases. The research aims to explore how modulating upstream disease mechanisms,...
- This federal Project Grant award for $637,913, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research by the University of Southern California (USC) to investigate the role of "transitional alveolar epithelial cells" in lung development and regeneration. The goal is to better understand the mechanisms underlying the alveolar epithelial cell differentiation process during normal lung development, as...
- This federal Project Grant award of $248,999 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research on mesenchymal cell plasticity and signaling in lung regeneration. The award aims to examine how specific mesenchymal cell lineages establish and maintain maladaptive epithelial regeneration after severe lung injury, such as from influenza or COVID-19. Key objectives include investigating the proliferation, plasticity, and Notch...
- This federal Project Grant award, titled "Regulation of Primary and Secondary Alveologenesis by FGF Signaling Pathways", was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The $740,317 award supports research conducted by The Washington University in St. Louis, Missouri to advance scientific understanding of alveolar development and lung regeneration. The research aims to investigate the mechanisms that regulate...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research into the mechanosensitive mechanisms underlying angiogenesis and lung regeneration. The $618,838 award to the Medical College of Wisconsin aims to investigate how mechanical stretching forces control angiogenesis during compensatory lung growth after pneumonectomy. The research will focus on the role of the focal adhesion protein paxillin in regulating...
- The federal Project Grant award of $108,978.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the mechanisms underlying the age-related decline in the regenerative capacity of alveolar type 2 (AT2) cells in the lung. The principal investigator and research team at the Harvard T.H. Chan School of Public Health will conduct studies to determine whether elevated interferon gamma (IFNG) levels and changes in resident...
- This federal Project Grant award of $722,584 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research on the role of the desmosome-keratin intermediate filament network in lung epithelial injury, repair, and regeneration. The research aims to explore how dysfunction or loss of this network may contribute to idiopathic pulmonary fibrosis (IPF). The award was made to Tulane University, a private research institution with expertise in...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $701,795 to The Trustees of the University of Pennsylvania to conduct research aimed at defining the cardinal functions of lung progenitors during regeneration. The 4-year project, which began in September 2025, utilizes a multi-modal approach including cell lineage tracing, single-cell analysis, histological spatial analysis, and cross-species comparison to...
- The Project Grant award titled "Alveolar Epithelial Stress Signaling in Lung Fibrosis" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $683,564.00 over the period of Jul 1, 2025 to Mar 31, 2030. The award supports comprehensive research focused on understanding the role of aberrant alveolar epithelial cells in the pathogenesis of pulmonary fibrosis, a devastating and progressive lung disease. The research aims to investigate...
- This Project Grant award, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the role of protein S-palmitoylation in TGF-beta signaling and fibrotic lung disease at Duke University. The $165,456 grant awarded on August 15, 2025 will fund a 5-year project to investigate how S-palmitoylation of the TGF-beta receptor regulates its activity and fibrotic pathways, and the potential for targeting related...
This federal Project Grant award of $811,370.00, provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to study the role of the Hippo-YAP/TAZ signaling pathway in regulating alveolar epithelial cell regeneration during lung repair. The research aims to determine the critical cellular and molecular mechanisms that facilitate normal alveolar repair and regeneration, with the overarching hypothesis that dynamic, cell-type-specific regulation of YAP and TAZ activity is essential to guide adaptive alveolar regeneration. The award, with a performance period from September 1, 2025 to August 31, 2030, will be conducted by Vanderbilt University Medical Center, a prominent academic medical center and federal grant recipient.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $811.4k | 8/1/25 |